Havana, Cuba: Cuban scientists today highlight the effectiveness of the drug Itolizumab, which showed positive results as an anti-inflammatory therapy treatment in patients with Covid-19, Prensa Latina publishes.
People positive for the virus can develop a very serious form, distinguished by the so-called cytokine storm syndrome.
This drug, being a molecule capable of blocking the proliferation and activation of T-lymphocytes, and which also behaves as an immune-modulator, has an effect associated with the reduction of the release of pro-inflammatory cytokines.
The use of this drug managed to reduce the concentrations of the cytokine IL-6 in the patients, even these showed respiratory and radiological improvement, and they recovered completely.
It is presumed that this anti-inflammatory therapy, in addition to antiviral and anticoagulant therapy, could reduce the morbidity and mortality associated with severe clinical forms of the virus, says the Granma newspaper.
Itolizumab is an anti-CD6 monoclonal antibody developed by the Center for Molecular Immunology.
This drug has been shown to be safe and effective in treating moderate to severe psoriasis.
In the fight against the SARS-CoV-2 virus, which causes Covid-19, the largest of the Antilles uses Nasalferon, Biomodulin T, Interferons and Jusvinza, among others.